Benefits and risks of primary prevention of venous thromboembolism in the elderly

Česká verzia

Authors: D. Weberová; H. Matějovská Kubešová; P. Weber
Authors place of work: Klinika interní, geriatrie a praktického lékařství LF MU a FN Brno
Published in the journal: Kardiol Rev Int Med 2018, 20(1): 36-40

Summary

Venous thromboembolism is a relatively common cardiovascular disease with a comparatively high morbidity and mortality. It includes two principal units – deep venous thrombosis and pulmonary embolism. The incidence and prevalence of venous thromboembolism increase exponentially with age. Therefore, there is no doubt about the importance of age as one of the principal risk factors causing this disorder. With increasing life expectancy, the relative and absolute numbers of patients suffering from this illness increases and will increase. Furthermore, geriatric patients show specific clinical signs, frequently suffer from polymorbidity and use polypharmacy. Therefore, they present a vulnerable group tending to develop venous thromboembolism with a higher risk of severe consequences as compared to younger adults. Accordingly, it is of high importance to primarily prevent venous thromboembolism in older patients considering their vulnerability to coagulability as well as to bleeding.

Key words:
venous thromboembolism – deep venous thrombosis – pulmonary embolism – prophylaxis – elderly patients – NOAC – polymorbidity – polypharmacotherapy

Zdroje

1. Musil D. Diagnostika a léčba tromboembolické nemoci z pohledu 10. ACCP doporučení. Interní Med 2017; 19(1): 7– 9.

2. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151(5): 933– 938.

3. Karetová D, Bultas J. Možnosti léčby hluboké žilní trombózy v roce 2014. Kardiol Rev Int Med 2014; 16(4): 330– 335.

4. Lacut K, Le Gal G, Mottier D. Primary prevention of venous thrombembolism in elderly medical patients. Clin Interv Aging 2008; 3(3): 399– 411.

5. Hirmerová J. Profylaxe žilních tromboembolických komplikací v interních oborech – rozpor mezi teorií a praxí. Vnitř Lék 2006; 52(4): 379– 388.

6. Musil D. Žilní tromboembolická nemoc a antikoagulační léčba u seniorů. Interní Med 2013; 15(3– 4): 94– 98.

7. Karetová D, Chochola M, Linhart A. Prevence trombembolické nemoci ve vnitřním lékařství. Čas Lék čes 2006; 145: 353– 357.

8. Heit JA, O’Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population based study. Arch Intern Med 2002; 162(11): 1245– 1248.

9. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82(4): 203– 205.

10. Ludka O. Antitrombotická léčba tromboembolické žilní nemoci. Interní Med 2016; 18(5): 222– 225.

11. International Consensus Statement – Prevention and treatment of venous thromboembolism (Guidelines according to scientific evidence). Int Angiol 2006; 25(2): 101– 161.

12. Lindbald B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302(6778): 709– 711.

13. Leizorovicz A, Cohen AT, Turpie A. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7): 874– 879.

14. Rokyta R, Hutyra M, Jansa P. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Summary document prepared by the Czech Society of Cardiology. Cor Vasa 2015; 57: 275– 296. doi: 10.1016/ j.crvasa.2015.05.009.

15. Kearon C, Akl EA, Omelas J et al. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest 2016; 149(2): 315– 352. doi: 10.1016/ j.chest.2015.11.026.

16. Musil D. Rizika a prevence tromboembolické choroby. Med Pro Praxi 2009; 6(2): 61– 65.

17. Shetty HG, Campbell IA, Routledge PA. Venous thromboembolism in the elderly. In: Fillit HM, Rockwood K, Woodhouse K et al. Brocklehurst’s textbook of geriatric medicine and gerontology. 7. vyd. Philadelphia, USA: Elsevier 2010: 356– 360.

18. Oger E. EPI-GETBO Study Group. Incidence of venous thrombembolism: a community-based study in Western France. Thromb Haemost 2000; 83(5): 657– 660.

19. Heit JA, Silverstein MD, Mohr DN et al. The epidemiology of venous thrombembolism in the community. Thromb Haemost 2001; 86(1): 452– 463.

20. Kniffin WD Jr, Baron JA, Barrett J et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154(8): 861– 866.

21. Weber P, Weberová D, Kubešová H. Pulmonary embolism in the elderly – Significance and particularities. In: Cobanoglu U. Pulmonary embolism. 1. vyd. Rijeka, Chorvatsko: InTech 2012: 37– 66.

22. Le Gal G, Righini M, Roy PM et al. Differential value of risk factors and clinical signs for diagnosing pulmonary embolism according to age. J Thromb Haemost 2005; 3(11): 2457– 2464. doi: 10.1111/ j.1538-7836.2005.01598.x.

23. Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA et al. RIETE Investigators. Venous thrombembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91(8): 1046– 1051.

24. Silverstein RL, Bauer KA, Cushman M et al. Venous thrombosis in the elderly: more questions than answers. Blood 2007; 110(9): 3097– 3101. doi: 10.1182/ blood-2007-06-096545.

25. White RH. The epidemiology of venous thrombembolism. Circulation 2003; 107 (23 Suppl 1): 14– 18.

26. Cobanoglu U. Risk factor for pulmonary embolism. In: Cobanoglu U. Pulmonary embolism. 1st ed. Rijeka, Chorvatsko: InTech 2012: 1– 18.

27. Weber P, Weberová D, Ambrošová P et al. Hluboká žilní trombóza a plicní embolie v geriatrické medicině – dvě strany jedné mince. Kardiol Rev 2012; 14(1): 17– 21.

28. Samama MH. An epidiomologic study of risk factors for deep venous thrombosis in medical outpatients: the SIRIUS study. Arch Intern Med 2000; 160(22): 3415– 3420.

29. Alikhan R, Cohen AT, Combe S et al. MEDENOX study. Risk factors for venous thrombembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164(9): 963– 968.

30. Vaitkus PT, Leizorovicz A, Cohen AT et al. PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep venous thrombosis in medical patients. Thromb Haemost 2005; 93(1): 76– 79. doi: 10.1160/ TH04-05-0323.

31. Spyropoulos AC. Risk assessment of venous thromboembolism in hospitalized medical patients. Cur Opin Pulm Med 2010; 16(5): 419– 425. doi: 10.1097/ MCP.0b013e32833b4669.

32. Khorana AA, Carrier M, Garcia DA et al. Guidance for the prevention and treatment of cancer-associated venous thrombembolism. J Thromb Thrombolysis 2016; 41(1): 81– 91. doi: 10.1007/ s11239-015-1313-4.

33. Garcia Escobar I, Antonio Rebollo M, García Adrián S et al. Cancer and Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM). Safety and efficacy of primary thromboprophylaxis in cancer patients. Clin Transl Oncol 2017; 19(1): 1– 11. doi: 10.1007/ s12094-016-1500-6.

34. Krška Z. Prevence TEN v chirurgii, prolongovaná tromboprofylaxe. Rozhl Chir 2012; 91(5): 256– 261.

35. Goldhaber SZ, Turpie AG. Prevention of venous thromboembolism among hospitalized patients. Circulation 2005; 111(1): e1– e3. doi: 10.1161/ 01.CIR.0000150393.51958.54.

36. Barbar S, Noventa F, Rossetto V et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8(11): 2450– 2457. doi: 10.1111/ j.1538-7836.2010.04044.x.

37. Germini F, Agnelli G, Fedele M et al. Padua Prediction Score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. J Thromb Thrombolysis 2016; 42(3): 336– 339. doi: 10.1007/ s11239-016-1358-z.

38. Palareti G, Schellong S. Isolated distal deep vein thrombosis: chat we know and chat we are doing. J Thromb Haemost 2012; 10(1): 11– 19. doi: 10.1111/ j.1538-7836.2011.04564.x.

39. Hlásenský J, Mihalová Z, Špinar J et al. Skórovací systémy u tromboembolické nemoci. Kardiol Rev Int Med 2015; 17(2): 126– 130.

40. Patell R, Rybicki L, McCrae KR et al. Predicitng risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Haematol 2017; 92(6): 501– 507. doi: 10.1002/ ajh.24700.

41. Bahl V, Hu HM, Henke PK et al. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010; 251(2): 344– 350. doi: 10.1097/ SLA.0b013e3181b7fca6.

42. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51(2– 3): 70– 78.

43. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic Therapy. Chest 2004; 126 (3 Suppl): 338S– 400S.

44. Mayer O. Nízkomolekulární hepariny v prevenci a léčbě žilního tromboembolizmu. Interní Med 2007; 1: 39– 41.

45. Bultas J, Karetová D. Nízkomolekulární hepariny – jejich význam v současné praxi. Interní Med 2011; 13(11): 440– 444.

46. Kessler P. Nízkomolekulární hepariny v ambulantní praxi. Interní Med 2010; 12(7 a 8): 361– 365.

47. Špác J. Nízkomolekulární hepariny v terapii kardiovaskulárních nemocí. Interní Med 2001; 2: 75– 79.

48. Palacka P, Hirmerová J. Dva pohľady na venózny tromboembolizmus u onkologických pacientov. Vnitř Lék 2017; 63(6): 431– 440.

49. Šmrha J, Kessler P, Poul H et al. Dlouhodobá léčba tromboembolické nemoci u pacientů se zhoubným nádorem. Vnitř Lék 2016; 62(6): 449– 452.

50. Bona RD, Sivjee KY, Hickey AD et al. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74(4): 1055– 1058.

51. Michalcová J, Penka M, Bulíková A. Nová – přímá perorální antikoagulancia: aktuální přehled. Vnitř Lék 2016; 62(10): 805– 813.

52. Janský P. Účinnost a bezpečnost dabigatranu při podávání dle SPC a evropských doporučení. Vnitř Lék 2017; 63(6): 450– 451.

53. Urbánek K. Rivaroxaban – farmakologický profil. Kardiol Rev Int Med 2017; 19(1): 39– 44.

54. Špinar J, Špinarová L. Rivaroxaban u rizikových pacientů. Vnitř Lék 2017; 63(6): 424– 430.

55. Lábrová R, Lábr K. Edoxaban – farmakologický profil. Kardiol Rev Int Med 2017; 19(1): 45– 50.

56. Kessler P. Nová antitrombotika v prevenci pooperační tromboemolické nemoci. Kardiol Rev 2012; 14(2): 93– 96.

57. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112(6): 423– 428.

58. An VV, Phan K, Levy Y et al. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systemic review and meta-analysis. J Arthroplasty 2016; 31(11): 2608– 2616. doi: 10.1016/ j.arth.2016.04.004.